跳至主要内容
临床试验/CTIS2024-510836-31-00
CTIS2024-510836-31-00招募中1 期

OATD-02-C-01

Molecure S.A.0 个研究点目标入组 40 人开始时间: 2024年3月15日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Molecure S.A.

相似试验

进行中(未招募)
1 期
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomasarge Granular Lymphocytic Leukemia or Cytotoxic LymphomasMedDRA version: 20.0Level: LLTClassification code: 10029430Term: NK-cell leukemia Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065862Term: T-cell large granular lymphocytic leukemia Class: 10029104
CTIS2023-503550-13-00Dren Bio Inc.116
进行中(未招募)
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359
CTIS2023-505605-16-00Oncorena AB50
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart Failure
CTIS2022-500347-20-00Anacardio AB116
招募中
1 期
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursAdvanced or refractory solid tumours
CTIS2023-504897-39-00Deuteroncology60
进行中(未招募)
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergy
CTIS2023-505783-11-00Alk-Abello A/S12
An open-label, multicentre, dose-escalation,... | 临床试验